Suxia Luo

6.6k total citations · 2 hit papers
108 papers, 3.5k citations indexed

About

Suxia Luo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Suxia Luo has authored 108 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Suxia Luo's work include Gastric Cancer Management and Outcomes (20 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Esophageal Cancer Research and Treatment (12 papers). Suxia Luo is often cited by papers focused on Gastric Cancer Management and Outcomes (20 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Esophageal Cancer Research and Treatment (12 papers). Suxia Luo collaborates with scholars based in China, United States and Italy. Suxia Luo's co-authors include Kongming Wu, Ming Yi, Linping Xu, Shuang Qin, Shengnan Yu, Mengke Niu, Anping Li, Bing Dong, Qian Chu and Ying Jiao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Suxia Luo

102 papers receiving 3.5k citations

Hit Papers

Novel immune checkpoint targets: moving beyond PD-1 and C... 2019 2026 2021 2023 2019 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    2019 858 citations Ming Yi, Kongming Wu et al. profile →
  2. Regulation of PD-L1 expression in the tumor microenvironment
    2021 440 citations Ming Yi, Mengke Niu et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suxia Luo China 25 2.0k 1.3k 993 793 745 108 3.5k
Savas D. Soysal Switzerland 23 2.0k 1.0× 1.2k 1.0× 1.1k 1.1× 431 0.5× 760 1.0× 77 3.5k
Oronzo Brunetti Italy 35 1.5k 0.8× 1.1k 0.9× 692 0.7× 525 0.7× 783 1.1× 126 3.1k
Sha Zhao China 30 1.4k 0.7× 1.5k 1.1× 1.2k 1.2× 785 1.0× 745 1.0× 97 3.4k
Kaoru Abiko Japan 25 2.4k 1.2× 965 0.8× 1.8k 1.9× 591 0.7× 557 0.7× 102 4.0k
Salman M. Toor Qatar 23 2.0k 1.0× 1.0k 0.8× 1.5k 1.5× 559 0.7× 429 0.6× 53 3.3k
Varun Sasidharan Nair Qatar 25 1.9k 0.9× 1.2k 0.9× 1.6k 1.6× 561 0.7× 409 0.5× 50 3.5k
Αthanasios Kotsakis Greece 35 2.5k 1.3× 1.0k 0.8× 717 0.7× 1.3k 1.6× 910 1.2× 166 3.6k
Pierosandro Tagliaferri Italy 34 1.7k 0.8× 1.1k 0.9× 645 0.6× 449 0.6× 615 0.8× 97 3.2k
Jun Gong United States 28 2.1k 1.1× 924 0.7× 660 0.7× 843 1.1× 569 0.8× 163 3.4k
Luis de la Cruz‐Merino Spain 26 2.6k 1.3× 1.9k 1.5× 812 0.8× 703 0.9× 541 0.7× 175 4.0k

Countries citing papers authored by Suxia Luo

Since Specialization
Citations

This map shows the geographic impact of Suxia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suxia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suxia Luo more than expected).

Fields of papers citing papers by Suxia Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suxia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suxia Luo. The network helps show where Suxia Luo may publish in the future.

Co-authorship network of co-authors of Suxia Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Suxia Luo. A scholar is included among the top collaborators of Suxia Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suxia Luo. Suxia Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fan, Zhengfu, Han Liang, Suxia Luo, et al.. (2025). Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial. Journal for ImmunoTherapy of Cancer. 13(1). e010543–e010543. 3 indexed citations
2.
3.
4.
Hou, Xinfang, et al.. (2023). Long noncoding RNA ZEB1‐AS1 attenuates ferroptosis of gastric cancer cells through modulating miR‐429/BGN axis. Journal of Biochemical and Molecular Toxicology. 37(8). e23381–e23381. 10 indexed citations
5.
Li, Jialiang, Suxia Luo, Tianbo Liu, et al.. (2023). 684P Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC). Annals of Oncology. 34. S478–S478. 8 indexed citations
6.
Chen, Naifei, Chengfei Pu, Lingling Zhao, et al.. (2023). A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). 3547–3547. 1 indexed citations
7.
Wu, Dawei, Meimei Chen, Jing Liang, et al.. (2022). Consensus on informed consent for participants in cancer clinical studies (2021 edition). Asia-Pacific Journal of Oncology Nursing. 9(11). 100130–100130. 4 indexed citations
8.
Li, Ning, Zhi Li, Qiang Fu, et al.. (2022). Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 40(4_suppl). 296–296. 7 indexed citations
9.
10.
Yi, Ming, Anping Li, Linghui Zhou, et al.. (2021). Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma. Cancer Immunology Immunotherapy. 70(6). 1705–1719. 96 indexed citations
11.
Cheng, Jiwei, Yongkui Yu, Baoxing Liu, et al.. (2021). Adjuvant treatment can improve prognosis in patients with non-small cell lung cancer ≤3 cm after sublobectomy: a propensity score analysis. Journal of Thoracic Disease. 13(1). 312–321. 1 indexed citations
12.
Yi, Ming, Jing Zhang, Anping Li, et al.. (2021). The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. Journal of Hematology & Oncology. 14(1). 27–27. 162 indexed citations
13.
Li, Ningning, Qiang Fu, Wenying Deng, et al.. (2020). 160P Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology. 31. S1302–S1302. 4 indexed citations
14.
Li, Ning, Wei Shen, Wenying Deng, et al.. (2020). Clinical features and the efficacy of adjuvant chemotherapy in resectable small bowel adenocarcinoma: a single-center, long-term analysis. Annals of Translational Medicine. 8(15). 949–949. 6 indexed citations
15.
Li, Shiyu, Ming Yi, Bing Dong, et al.. (2020). The roles of exosomes in cancer drug resistance and its therapeutic application. SHILAP Revista de lepidopterología. 10(8). 82 indexed citations
16.
17.
Fu, Qiang, et al.. (2017). [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].. PubMed. 20(5). 566–570. 13 indexed citations
18.
Fu, Qiang, Jing Cheng, Yonglei Zhang, et al.. (2016). Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. Oncology Reports. 36(6). 3682–3690. 32 indexed citations
19.
20.
Fang, Baijun, Suxia Luo, Yongping Song, Ning Li, & Ying Cao. (2009). Hemangioblastic Characteristics of Human Adipose Tissue-derived Adult Stem Cells In Vivo. Archives of Medical Research. 40(4). 311–317. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Savas D. Soysal Breakdown of academic impact, for papers by Oronzo Brunetti Breakdown of academic impact, for papers by Sha Zhao Breakdown of academic impact, for papers by Kaoru Abiko Breakdown of academic impact, for papers by Salman M. Toor Breakdown of academic impact, for papers by Varun Sasidharan Nair Breakdown of academic impact, for papers by Αthanasios Kotsakis Breakdown of academic impact, for papers by Pierosandro Tagliaferri Breakdown of academic impact, for papers by Jun Gong Breakdown of academic impact, for papers by Luis de la Cruz‐Merino
Rankless by CCL
2026